Serum ornithine carbamyltransferase reflects hepatic damage in diabetic obese mice

被引:2
作者
Murayama, Hiroshi [1 ]
Ikemoto, Masaki [2 ]
Hamaoki, Masaru [1 ]
机构
[1] Yamasa Corp, Diagnost Dept, Chiba 2880056, Japan
[2] Kyoto Univ, Fac Med, Sch Hlth Sci, Kyoto, Japan
关键词
alanine aminotransferase; mitochondria; non-alcoholic fatty liver disease; ornithine carbamyltransferase; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; ANIMAL-MODELS; INJURY; ADIPONECTIN; NASH; PURIFICATION; PATHOGENESIS; EXTRUSION;
D O I
10.1111/j.1440-1746.2009.05969.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: As ornithine carbamyltransferase (OCT) has proved to be a sensitive serum marker in the detection of hepatotoxicity in several models, it is important to confirm its application to the diagnosis of non-alcoholic fatty liver disease. Methods: C57BL/6, KK-Ta and KK-Ay mice were fed a high-fat diet for 8 weeks and serum enzyme markers were examined. Serum OCT and alanine aminotransferase (ALT) were also measured in diabetic obese ob/ob and db/db mice fed a normal diet. Liver damage in these mice was evaluated by the hepatic content of tumor necrosis factor-alpha. Results: Serum levels of OCT increased in KK-Ay fed a high-fat diet compared with the normal diet-fed group, whereas C57BL/6 and KK-Ta mice were not affected. In ob/ob mice, the relative increase was always greater in OCT than in ALT. In contrast, in db/db mice, the relative increase was always greater in ALT. Hepatic tumor necrosis factor-alpha was significantly elevated in ob/ob mice, but not in db/db mice. Conclusions: Serum OCT seemed to reflect tumor necrosis factor-alpha-mediated hepatic damage when compared with ALT in diabetic obese mice and could be useful in the application for non-alcoholic fatty liver disease with features of metabolic syndrome, such as obesity and diabetes.
引用
收藏
页码:413 / 419
页数:7
相关论文
共 41 条
  • [1] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [2] Mouse models in non-alcoholic fatty liver disease and steatohepatitis research
    Anstee, QM
    Goldin, RD
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2006, 87 (01) : 1 - 16
  • [3] NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY
    BACON, BR
    FARAHVASH, MJ
    JANNEY, CG
    NEUSCHWANDERTETRI, BA
    [J]. GASTROENTEROLOGY, 1994, 107 (04) : 1103 - 1109
  • [4] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [5] BROHULT J, 1969, ACTA MED SCAND, V185, P357
  • [6] Mitochondrial abnormalities in non-alcoholic steatohepatitis
    Caldwell, SH
    Swerdlow, RH
    Khan, EM
    Iezzoni, JC
    Hespenheide, EE
    Parks, JK
    Parker, WD
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 (03) : 430 - 434
  • [7] Lessons from animal models of NASH
    Diehl, AM
    [J]. HEPATOLOGY RESEARCH, 2005, 33 (02) : 138 - 144
  • [8] Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis
    Feldstein, AE
    Canbay, A
    Angulo, P
    Taniai, M
    Burgart, LJ
    Lindor, KD
    Gores, GJ
    [J]. GASTROENTEROLOGY, 2003, 125 (02) : 437 - 443
  • [9] FOLCH J, 1957, J BIOL CHEM, V226, P497
  • [10] The ins and outs of mitochondrial dysfunction in NASH
    Fromenty, B
    Robin, M
    Igoudjil, A
    Mansouri, A
    Pessayre, D
    [J]. DIABETES & METABOLISM, 2004, 30 (02) : 121 - 138